Search Share Prices
C4X Discovery enters research collaboration to develop Parkinson's drugs
Drug discovery firm C4X Discovery on Tuesday said that it has entered into a research collaboration with e-Therapeutics plc.
The collaboration will see the utilisation of both companies' drug discovery technologies, particularly C4XD's Taxonomy3 novel target identification platform and e-Therapeutics' Network-driven Drug Discovery (NDD) capabilities, to identify novel mechanistic insights into Parkinson's Disease (PD).
C4XD's Taxonomy3 technology has already identified 180 novel disease associated genes with PD and has also identified sub-groups of patients, which has the potential to provide an opportunity for the development of stratified medicine.
At the beginning of 2017 just 40 PD associated genes were acknowledged in scientific literature.
As such, C4XD has indicated that the combination of its PD genetics knowledge and e-Therapeutics' NDD capabilities will reveal further disease insights and could lead to additional drug discovery programmes.
Craig Fox, chief scientific officer at C4X Discovery, said: "This collaboration not only demonstrates the potential of C4XD's drug discovery technologies but also highlights our desire to maximise the value from our novel genetic analysis by accessing complementary and synergistic proprietary technologies. This strategy will most effectively support our pursuit of licensable pre-clinical drug assets, such as the Orexin-1 receptor antagonist recently licensed to Indivior for up to $294m."
As of 0828 BST, C4X Discovery's shares were down 2.26% at 108.00p.